title: Life-threatening toxic epidermal necrolysis during voriconazole therapy for invasive aspergillosis after chemotherapy.
authors.forename: G
authors.initials: G
authors.lastname: Curigliano
authors.forename: V
authors.initials: V
authors.lastname: Formica
authors.forename: T
authors.initials: T
authors.lastname: De Pas
authors.forename: G
authors.initials: G
authors.lastname: Spitaleri
authors.forename: E
authors.initials: E
authors.lastname: Pietri
authors.forename: N
authors.initials: N
authors.lastname: Fazio
authors.forename: F
authors.initials: F
authors.lastname: de Braud
authors.forename: A
authors.initials: A
authors.lastname: Goldhirsch
mesh_terms: D000328:Adult; D000927:Anticonvulsants / Q000627:therapeutic use; D000935:Antifungal Agents / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001228:Aspergillosis / Q000188:drug therapy*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology; D004347:Drug Interactions; D006801:Humans; D008172:Lung Diseases, Fungal / Q000188:drug therapy*; D008297:Male; D010672:Phenytoin / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects*; D013262:Stevens-Johnson Syndrome / Q000209:etiology*; D014230:Triazoles / Q000009:adverse effects*; D065819:Voriconazole
chemical_list: D000927:Anticonvulsants; D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D010672:Phenytoin; D065819:Voriconazole